Baidu
map

心血管指南

订阅

MedSci主页 / 所有栏目 / 心血管指南

2020 CCS/CTS立场声明：肺动脉高压

2020-07-15 加拿大心血管学会 Can J Cardiol . 2020 Jul;36(7):977-992.

肺动脉高压

2020年7月，加拿大心血管学会(CCS)联合加拿大胸科学会(CTS)共同发布了肺动脉高压立场声明。自加拿大上一次于2005年发布肺动脉高压立场声明以来，关于肺动脉高压的诊断和治疗领域已经发生了许多改

中文标题：

2020 CCS/CTS立场声明：肺动脉高压

英文标题：

Canadian Cardiovascular Society/Canadian Thoracic Society Position Statement on Pulmonary Hypertension

发布机构：

加拿大心血管学会

发布日期：

2020-07-15

简要介绍：

2020年7月，加拿大心血管学会(CCS)联合加拿大胸科学会(CTS)共同发布了肺动脉高压立场声明。自加拿大上一次于2005年发布肺动脉高压立场声明以来，关于肺动脉高压的诊断和治疗领域已经发生了许多改变。本文主要介绍了最新肺动脉高压的筛查和诊断框架，并对超声心动图。磁共振以及右心导管插入术的相关内容提出指导建议，同时还涉及肺动脉高压治疗的最新内容。

相关资料下载：
[AttachmentFileName(sort=1, fileName=2020 CCS_CTS立场声明：肺动脉高压.pdf)] GetToolGuiderByIdResponse(projectId=1, id=d40451c0019a0e6f, title=2020 CCS/CTS立场声明：肺动脉高压, enTitle=Canadian Cardiovascular Society/Canadian Thoracic Society Position Statement on Pulmonary Hypertension, guiderFrom=Can J Cardiol . 2020 Jul;36(7):977-992., authorId=0, author=, summary=2020年7月，加拿大心血管学会(CCS)联合加拿大胸科学会(CTS)共同发布了肺动脉高压立场声明。自加拿大上一次于2005年发布肺动脉高压立场声明以来，关于肺动脉高压的诊断和治疗领域已经发生了许多改, cover=https://img.medsci.cn/2020727/1595779793959_2020535.jpg, journalId=0, articlesId=null, associationId=263, associationName=加拿大心血管学会, associationIntro=加拿大心血管学会(CCS)通过传播研究结果和最佳治疗，促进心血管健康。《加拿大心脏病学期刊》（The Canadian Journal of Cardiology,CJC）是加拿大心血管学会(Canadian Cardiovascular Society,CCS)的官方期刊。本刊面向国际，发布心脏病学与心血管病科学新知识，是加拿大心血管学研究成果与加拿大心血管学会指导方针的主要发布场所。本刊发表与心血管医学相关的临床与基础研究的原创报告、社论、评审文章、案例报告，以及关于保健结果、政策研究、道德伦理、医学历史与医学政策问题的论文。, copyright=0, guiderPublishedTime=Wed Jul 15 00:00:00 CST 2020, originalUrl=, linkOutUrl=, content=<div class="one_info2" style="color: #373737;"> <div id="all_content"> <div class="editor_mirror editor_mirror_del"> <p>2020年7月，加拿大心血管学会(CCS)联合加拿大胸科学会(CTS)共同发布了肺动脉高压立场声明。自加拿大上一次于2005年发布肺动脉高压立场声明以来，关于肺动脉高压的诊断和治疗领域已经发生了许多改变。本文主要介绍了最新肺动脉高压的筛查和诊断框架，并对超声心动图。磁共振以及右心导管插入术的相关内容提出指导建议，同时还涉及肺动脉高压治疗的最新内容。</p> </div> </div> </div>, tagList=[TagDto(tagId=1179, tagName=肺动脉高压)], categoryList=[CategoryDto(categoryId=2, categoryName=心血管, tenant=100), CategoryDto(categoryId=12, categoryName=呼吸, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=1179, guiderKeyword=肺动脉高压, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=1, guiderRegion=4, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=4519, appHits=457, showAppHits=0, pcHits=1033, showPcHits=4062, likes=5, shares=13, comments=26, approvalStatus=1, publishedTime=Mon Jul 27 00:11:20 CST 2020, publishedTimeString=2020-07-15, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=qiushida2, createdTime=Mon Jul 27 00:10:01 CST 2020, updatedBy=2020535, updatedName=qiushida2, updatedTime=Sat Jan 06 20:04:49 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2020 CCS_CTS立场声明：肺动脉高压.pdf)])
2020 CCS_CTS立场声明：肺动脉高压.pdf
下载请点击：
评论区 (20)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=947561, encodeId=3a1894e5615c, content=文件不全, beContent=null, objectType=guider, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210702/8a504bc7b34f4551a94e20c1772f881d/52715005a10d47408c045c7f76ae5dce.jpg, createdBy=c9ab5417745, createdName=ms9000001670464210, createdTime=Fri Mar 12 01:21:00 CST 2021, time=2021-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=927243, encodeId=91f092e2436b, content=看不了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bf3d5463253, createdName=ms1000000120306872, createdTime=Thu Feb 25 22:30:53 CST 2021, time=2021-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=916813, encodeId=526b916813e7, content=看不了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eac45422606, createdName=ms7000000096343979, createdTime=Fri Jan 15 09:40:33 CST 2021, time=2021-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=916178, encodeId=2d4d9161e87b, content=看不了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21a85451908, createdName=ms4000000061192183, createdTime=Wed Jan 13 10:48:09 CST 2021, time=2021-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=912309, encodeId=3a899123090a, content=看不了，只有第一页，后面的都没有内容, beContent=null, objectType=guider, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9cc05442693, createdName=ms1000000382757898, createdTime=Wed Dec 30 21:17:28 CST 2020, time=2020-12-30, status=1, ipAttribution=)]
    2021-03-12 ms9000001670464210

    文件不全

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=947561, encodeId=3a1894e5615c, content=文件不全, beContent=null, objectType=guider, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210702/8a504bc7b34f4551a94e20c1772f881d/52715005a10d47408c045c7f76ae5dce.jpg, createdBy=c9ab5417745, createdName=ms9000001670464210, createdTime=Fri Mar 12 01:21:00 CST 2021, time=2021-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=927243, encodeId=91f092e2436b, content=看不了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bf3d5463253, createdName=ms1000000120306872, createdTime=Thu Feb 25 22:30:53 CST 2021, time=2021-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=916813, encodeId=526b916813e7, content=看不了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eac45422606, createdName=ms7000000096343979, createdTime=Fri Jan 15 09:40:33 CST 2021, time=2021-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=916178, encodeId=2d4d9161e87b, content=看不了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21a85451908, createdName=ms4000000061192183, createdTime=Wed Jan 13 10:48:09 CST 2021, time=2021-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=912309, encodeId=3a899123090a, content=看不了，只有第一页，后面的都没有内容, beContent=null, objectType=guider, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9cc05442693, createdName=ms1000000382757898, createdTime=Wed Dec 30 21:17:28 CST 2020, time=2020-12-30, status=1, ipAttribution=)]
    2021-02-25 ms1000000120306872

    看不了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=947561, encodeId=3a1894e5615c, content=文件不全, beContent=null, objectType=guider, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210702/8a504bc7b34f4551a94e20c1772f881d/52715005a10d47408c045c7f76ae5dce.jpg, createdBy=c9ab5417745, createdName=ms9000001670464210, createdTime=Fri Mar 12 01:21:00 CST 2021, time=2021-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=927243, encodeId=91f092e2436b, content=看不了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bf3d5463253, createdName=ms1000000120306872, createdTime=Thu Feb 25 22:30:53 CST 2021, time=2021-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=916813, encodeId=526b916813e7, content=看不了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eac45422606, createdName=ms7000000096343979, createdTime=Fri Jan 15 09:40:33 CST 2021, time=2021-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=916178, encodeId=2d4d9161e87b, content=看不了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21a85451908, createdName=ms4000000061192183, createdTime=Wed Jan 13 10:48:09 CST 2021, time=2021-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=912309, encodeId=3a899123090a, content=看不了，只有第一页，后面的都没有内容, beContent=null, objectType=guider, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9cc05442693, createdName=ms1000000382757898, createdTime=Wed Dec 30 21:17:28 CST 2020, time=2020-12-30, status=1, ipAttribution=)]
    2021-01-15 ms7000000096343979

    看不了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=947561, encodeId=3a1894e5615c, content=文件不全, beContent=null, objectType=guider, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210702/8a504bc7b34f4551a94e20c1772f881d/52715005a10d47408c045c7f76ae5dce.jpg, createdBy=c9ab5417745, createdName=ms9000001670464210, createdTime=Fri Mar 12 01:21:00 CST 2021, time=2021-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=927243, encodeId=91f092e2436b, content=看不了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bf3d5463253, createdName=ms1000000120306872, createdTime=Thu Feb 25 22:30:53 CST 2021, time=2021-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=916813, encodeId=526b916813e7, content=看不了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eac45422606, createdName=ms7000000096343979, createdTime=Fri Jan 15 09:40:33 CST 2021, time=2021-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=916178, encodeId=2d4d9161e87b, content=看不了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21a85451908, createdName=ms4000000061192183, createdTime=Wed Jan 13 10:48:09 CST 2021, time=2021-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=912309, encodeId=3a899123090a, content=看不了，只有第一页，后面的都没有内容, beContent=null, objectType=guider, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9cc05442693, createdName=ms1000000382757898, createdTime=Wed Dec 30 21:17:28 CST 2020, time=2020-12-30, status=1, ipAttribution=)]
    2021-01-13 ms4000000061192183

    看不了

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=947561, encodeId=3a1894e5615c, content=文件不全, beContent=null, objectType=guider, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210702/8a504bc7b34f4551a94e20c1772f881d/52715005a10d47408c045c7f76ae5dce.jpg, createdBy=c9ab5417745, createdName=ms9000001670464210, createdTime=Fri Mar 12 01:21:00 CST 2021, time=2021-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=927243, encodeId=91f092e2436b, content=看不了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bf3d5463253, createdName=ms1000000120306872, createdTime=Thu Feb 25 22:30:53 CST 2021, time=2021-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=916813, encodeId=526b916813e7, content=看不了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eac45422606, createdName=ms7000000096343979, createdTime=Fri Jan 15 09:40:33 CST 2021, time=2021-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=916178, encodeId=2d4d9161e87b, content=看不了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21a85451908, createdName=ms4000000061192183, createdTime=Wed Jan 13 10:48:09 CST 2021, time=2021-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=912309, encodeId=3a899123090a, content=看不了，只有第一页，后面的都没有内容, beContent=null, objectType=guider, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9cc05442693, createdName=ms1000000382757898, createdTime=Wed Dec 30 21:17:28 CST 2020, time=2020-12-30, status=1, ipAttribution=)]
    2020-12-30 ms1000000382757898

    看不了，只有第一页，后面的都没有内容

    0

以上为热门评论，梅斯医学App还有更多内容

相关指南

2018 TSOC指南：肺动脉高压的诊断和治疗（更新版）

台湾心脏病学会(TSOC,Taiwan Society of Cardiology) · 2019-03-26

2018 CHEST指南：成人肺动脉高压的治疗

美国胸科医师学会(ACCP,American College of Chest Physicians) · 2019-01-14

2018 科隆共识会议建议：成人先天性心脏病患者肺动脉高压

国外心血管相关专家小组（统称） · 2018-08-25

2018 科隆共识会议建议：肺动脉高压的定义，临床分类和初始诊断

国外呼吸科专家组（统称） · 2018-08-27

新生儿肺动脉高压诊治专家共识

中华医学会儿科学分会新生儿学组 · 2017-03-30

2015 ESC/ERS指南：肺动脉高压的诊断与治疗

欧洲心脏病学会(ESC,European Society of Cardiology) · 2015-08-29

拓展阅读

2011AHA 大面积和次大面积肺栓塞、髂股深静脉血栓形成以及慢性血栓栓塞性肺动脉高压的治疗指南

美国心脏协会(AHA,American Heart Association) · 2011-04-21

先天性心脏病相关肺动脉高压中国专家共识

中华医学会心血管病学分会(Chinese Society of Cardiology) · 2012-12-01

2013先天性心脏病相关性肺动脉高压诊治专家共识

中国心血管病相关专家小组（统称） · 2013-05-16

2014 肺动脉高压治疗流程

中国呼吸科专家组（统称） · 2014-01-02

2014 ATS临床实践指南：美国镰状细胞贫血患者肺动脉高压的诊断危险分层和管理

美国胸科学会(ATS,American Thoracic Society) · 2014-03-15

2014 ACCP成人肺动脉高压药物治疗指南

美国胸科医师学会(ACCP,American College of Chest Physicians) · 2014-06-17

Baidu
map
Baidu
map
Baidu
map